文献速递中医内科中药与中成药合理使用

RUTI试验:探索中药治疗复发性尿路感染可行性的研究

The RUTI trial: A feasibility study exploring Chinese herbal medicine for the treatment of recurrent urinary tract infections.
PubMed 文献 · J Ethnopharmacol · 2019-05-10

本研究评估在英国NHS初级保健中开展标准化与个体化中药治疗复发性尿路感染(RUTI)的可行性。结果显示监管审批可行,但通过NHS招募缓慢;个体化组在自我帮助网络招募的保留率和数据收集可接受,症状改善和抗生素使用减少的初步数据有希望,但标准化组保留和数据收集存在问题,每日症状日记不适合持续感染女性。

要点

  • 中药作为研究性药品的监管审批可行。
  • 通过NHS初级保健招募和治疗RUTI患者目前不可行。
  • 个体化中药组显示症状改善和抗生素使用减少的初步信号。

核心结论

  • 中药能满足CTIMP研究的严格要求,但当前通过NHS初级保健招募和治疗RUTI患者可能不可行。
  • 通过自我帮助小组的招募和保留率可接受,且个体化组初步结果有希望,值得开展完整试验。

研究设计与样本

  • 安慰剂对照、双盲随机对照可行性试验,比較标准化中药与安慰剂(由全科医生给药)以及个体化中药与安慰剂(由经验丰富的中药医师给药)。

主要发现

  • 标准化组(n=30)的保留和数据收集存在问题,而个体化组(n=31)可接受。
  • 每日症状日记不适合持续感染的女性作为结局指标。
  • 个体化组在试验期间和之后症状改善及抗生素使用减少方面显示有希望的初步数据。

关键数值与推荐

  • 主要可行性结局包括:获得监管批准、招募、随机化、保留、安全性及结局指标的相关性。

临床怎么用

  • 个体化中药在RUTI治疗中可能具有减少抗生素使用的潜力,但需进一步完整试验验证。
  • 当前不建议通过NHS初级保健途径开展此类中药试验。

局限性

  • 招募缓慢,需依赖非NHS自我帮助网络寻找个体化组参与者。
  • 标准化组的保留和数据收集存在问题。
  • 每日症状日记不适用于持续感染女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

ETHNOPHARMACOLOGICAL RELEVANCE: Chinese herbal medicine (CHM) is a widely used traditional intervention that may have a role to play in addressing the global problem of antimicrobial resistance in conditions such as recurrent urinary tract infections (RUTIs). AIM OF THE STUDY: To evaluate the feasibility of administering standardised and individualised formulations of CHM for RUTIs as a Clinical Trial of an Investigational Medicinal Product (CTIMP) within primary care of the UKs National Health Service (NHS). MATERIALS AND METHODS: Regulatory approval was applied for a placebo controlled, double blinded randomised controlled feasibility trial comparing a) standardised CHM vs placebo administered via General practitioners, and b) individualised CHM vs placebo administered by an experienced CHM practitioner. Primary feasibility outcomes included: gaining regulatory approval, recruitment, randomisation, retention, safety and the relevance of outcomes measures. RESULTS: Regulatory approval for testing CHM as a CTIMP was successfully obtained. Recruitment to the trial was slow and non-NHS self help networks were required to find participants for the individualised arm (n = 31). Retention and data collection in the standardised arm (n-30) were problematic, but these were acceptable in the individualised arm. The use of a daily symptom diary was not a suitable outcome measure for women with continuous infection. Other measures showed promising preliminary data for the individualised arm on improvement in symptoms, and reduction in antibiotic use during and after the trial. CONCLUSION: CHM can fulfil the demanding requirements of a CTIMP study but it may not be feasible at this point in time to recruit and treat via NHS primary care. However acceptable rates of recruitment and retention via self-help groups and promising preliminary results in the individualised arm suggest it would be worth testing this approach in a full trial.

来源:J Ethnopharmacol,查看原文。版权归原作者所有。

引用

  1. Flower A, Harman K, Willcox M, et al. The RUTI trial: A feasibility study exploring Chinese herbal medicine for the treatment of recurrent urinary tract infections. J Ethnopharmacol. 2019. PMID: 31082512. doi:10.1016/j.jep.2019.111935

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。